Lives could be saved thanks to rapid diagnostic technology that will be developed by a new research arm recently announced by a Scottish trace detection company.
Strathclyde University spin out company D3 Technologies is to establish a research and development and processing base for clinical molecular diagnostic products in Glasgow, which will lead to quicker and more effective detection and treatment of diseases.
The company’s new investment will create 22 high value jobs located in the Nova Business Park in Glasgow and is being supported with a Regional Selective Assistance grant of £250,000.
The company’s expertise in surface enhanced Raman spectroscopy and DNA chemistry has led to the development of products which will be the first in the world to examine single samples of blood and other substances for several diseases simultaneously.
‘Early detection means earlier intervention and better patient care,’ said Jim Reid, founder and director of D3 Technologies. ‘Screening for multiple bacteria and viruses one by one using current methods takes time, something that many patients can’t afford.
‘This investment will allow us to continue to develop these products, link into a network of clinical test centres in Europe and to continue our excellent working relationship with the research group at Strathclyde University.’